563 related articles for article (PubMed ID: 30218397)
1. Clinical management of Duchenne muscular dystrophy: the state of the art.
Messina S; Vita GL
Neurol Sci; 2018 Nov; 39(11):1837-1845. PubMed ID: 30218397
[TBL] [Abstract][Full Text] [Related]
2. Duchenne muscular dystrophy: an updated review of common available therapies.
Salmaninejad A; Valilou SF; Bayat H; Ebadi N; Daraei A; Yousefi M; Nesaei A; Mojarrad M
Int J Neurosci; 2018 Sep; 128(9):854-864. PubMed ID: 29351004
[TBL] [Abstract][Full Text] [Related]
3. An Overview of Recent Therapeutics Advances for Duchenne Muscular Dystrophy.
Mah JK
Methods Mol Biol; 2018; 1687():3-17. PubMed ID: 29067652
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
5. [Mutation-specific treatments for Duchenne muscular dystrophy].
Matsuo M; Takeshima Y
Brain Nerve; 2009 Aug; 61(8):915-22. PubMed ID: 19697880
[TBL] [Abstract][Full Text] [Related]
6. Exon-skipping therapy for Duchenne muscular dystrophy.
Nakamura A; Takeda S
Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
[TBL] [Abstract][Full Text] [Related]
7. Contributions of Japanese patients to development of antisense therapy for DMD.
Matsuo M; Takeshima Y; Nishio H
Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
[TBL] [Abstract][Full Text] [Related]
8. Genetic diagnosis as a tool for personalized treatment of Duchenne muscular dystrophy.
Bello L; Pegoraro E
Acta Myol; 2016 Dec; 35(3):122-127. PubMed ID: 28484312
[TBL] [Abstract][Full Text] [Related]
9. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
[TBL] [Abstract][Full Text] [Related]
10. Common therapeutic advances for Duchenne muscular dystrophy (DMD).
Salmaninejad A; Jafari Abarghan Y; Bozorg Qomi S; Bayat H; Yousefi M; Azhdari S; Talebi S; Mojarrad M
Int J Neurosci; 2021 Apr; 131(4):370-389. PubMed ID: 32241218
[No Abstract] [Full Text] [Related]
11. Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy.
Meyers TA; Townsend D
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31443395
[TBL] [Abstract][Full Text] [Related]
12. Duchenne muscular dystrophy: genome editing gives new hope for treatment.
Crispi V; Matsakas A
Postgrad Med J; 2018 May; 94(1111):296-304. PubMed ID: 29386334
[TBL] [Abstract][Full Text] [Related]
13. Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
Echigoya Y; Yokota T
Nucleic Acid Ther; 2014 Feb; 24(1):57-68. PubMed ID: 24380394
[TBL] [Abstract][Full Text] [Related]
14. Duchenne and Becker muscular dystrophies.
Flanigan KM
Neurol Clin; 2014 Aug; 32(3):671-88, viii. PubMed ID: 25037084
[TBL] [Abstract][Full Text] [Related]
15. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
[TBL] [Abstract][Full Text] [Related]
16. Duchenne Muscular Dystrophy: A Practice Update.
Suthar R; Sankhyan N
Indian J Pediatr; 2018 Apr; 85(4):276-281. PubMed ID: 28653137
[TBL] [Abstract][Full Text] [Related]
17. [Molecular therapies for Duchenne muscular dystrophy].
Takeshima Y
No To Hattatsu; 2016 Jul; 48(4):241-6. PubMed ID: 30010301
[TBL] [Abstract][Full Text] [Related]
18. Mutation spectrum analysis of Duchenne/Becker muscular dystrophy in 68 families in Kuwait: The era of personalized medicine.
Mohammed F; Elshafey A; Al-Balool H; Alaboud H; Al Ben Ali M; Baqer A; Bastaki L
PLoS One; 2018; 13(5):e0197205. PubMed ID: 29847600
[TBL] [Abstract][Full Text] [Related]
19. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
[TBL] [Abstract][Full Text] [Related]
20. Duchenne and Becker muscular dystrophy: from gene diagnosis to molecular therapy.
Matsuo M
IUBMB Life; 2002 Mar; 53(3):147-52. PubMed ID: 12102170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
